Predicting Survival of Patients With Rectal Neuroendocrine Tumors Using Machine Learning: A SEER-Based Population Study

利用机器学习预测直肠神经内分泌肿瘤患者的生存率:一项基于SEER数据库的人群研究

阅读:1

Abstract

Background: The number of patients diagnosed with rectal neuroendocrine tumors (R-NETs) is increasing year by year. An integrated survival predictive model is required to predict the prognosis of R-NETs. The present study is aimed at exploring epidemiological characteristics of R-NETs based on a retrospective study from the Surveillance, Epidemiology, and End Results (SEER) database and predicting survival of R-NETs with machine learning. Methods: Data of patients with R-NETs were extracted from the SEER database (2000-2017), and data were also retrospectively collected from a single medical center in China. The main outcome measure was the 5-year survival status. Risk factors affecting survival were analyzed by Cox regression analysis, and six common machine learning algorithms were chosen to build the predictive models. Data from the SEER database were divided into a training set and an internal validation set according to the year 2010 as a time point. Data from China were chosen as an external validation set. The best machine learning predictive model was compared with the American Joint Committee on Cancer (AJCC) seventh staging system to evaluate its predictive performance in the internal validation dataset and external validation dataset. Results: A total of 10,580 patients from the SEER database and 68 patients from a single medical center were included in the analysis. Age, gender, race, histologic type, tumor size, tumor number, summary stage, and surgical treatment were risk factors affecting survival status. After the adjustment of parameters and algorithms comparison, the predictive model using the eXtreme Gradient Boosting (XGBoost) algorithm had the best predictive performance in the training set [area under the curve (AUC) = 0.87, 95%CI: 0.86-0.88]. In the internal validation, the predictive ability of XGBoost was better than that of the AJCC seventh staging system (AUC: 0.90 vs. 0.78). In the external validation, the XGBoost predictive model (AUC = 0.89) performed better than the AJCC seventh staging system (AUC = 0.83). Conclusions: The XGBoost algorithm had better predictive power than the AJCC seventh staging system, which had a potential value of the clinical application.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。